Search Results - "Harmandali, Aybuke"

An Interim Analysis of the Turkish Myeloma Registry Among the Patients Who Have Received up to Two Lines of Therapy by Sevindik, Omur Gokmen, Ozkurt, Zubeyde Nur, Boga, Can, Besisik, Sevgi Kalayoglu, Ipek, Yildiz, Geduk, Ayfer, Harmandali, Aybuke, Salihoglu, Ayse, Sahin, Handan haydaroglu, Sönmez, Mehmet, Vural, Filiz, Akay, Olga Meltem, Kurt Yuksel, Meltem, Maral, Senem, Ekinci, Omer, Kirkizlar, Onur Hakki, Tekinalp, Atakan, Demir, Nazli, Merter, Mustafa, Saydam, Guray, Alacacıoğlu, İnci, Yegin, Zeynep Arzu, Kasar, Mutlu, Mastanzade, Metban, Ozsan, Guner Hayri

“…Introduction: To investigate the demographics and treatment details of the myeloma patients who were diagnosed and followed up in Turkey and received up to two…”
Get full text

Real-World Data in Relapsed Refractory Myeloma Patients Treated with Carfilzomib, a Multicenter Turkish Experience by Sevindik, Omur Gokmen, Pehlivan, Mustafa, Tuglular, Tulin F, Solmaz, Serife M, Dogu, Mehmet Hilmi, Yalniz, Fevzi, Ural, Ali Ugur, Yeğen, Zafer Serenli, Arat, Mutlu, Ozkocaman, Vildan, Umit, Elif G, Şahin, Handan Haydaroğlu, Sönmez, Mehmet, Turgut, Mehmet, Ozcan, Muhit, Arslan, Onder, Aydin, Yildiz, Elibol, Tayfun, Harmandali Olgun, Aybuke, Bayar, Banu, Tombak, Anil, Aydogdu, Ismet, Özsan, Güner Hayri

“…Introduction: Carfilzomib is a potent and irreversible inhibitor of proteasome which exerts clinically significant anti-myeloma effect. Randomized phase 2 and…”
Get full text

P-125: An interim analysis of the Turkish Myeloma Registry among patients who have received up to two lines of therapy by Sevindik, Omur Gokmen, Özkurt, Zübeyde Nur, Boğa, Can, Besisik, Sevgi Kalayoglu, Ipek, Yıldız, Gedük, Ayfer, Harmandalı, Aybüke, Salihoğlu, Ayşe, Şahin, Handan Haydaroğlu, Sönmez, Mehmet, Vural, Filiz, Akay, Olga Meltem, Yüksel, Meltem Kurt, Maral, Senem, Ekinci, Ömer, Kırkızlar, Hakkı Onur, Tekinalp, Atakan, Demir, Nazlı, Merter, Mustafa, Saydam, Güray, Alacacioğlu, inci, Yeğin, Zeynep Arzu, Kasar, Mutlu, Mastanzade, Metban, Özsan, Güner Hayri

“…To investigate the demographics and treatment details of the myeloma patients who were diagnosed and followed up in Turkey and received up to two lines of…”
Get full text